



# PlantVax



**Contact:**  
Yvonne Rosenberg

**Location:**  
Rockville, MD

**Email:**  
[yrosenther@aol.com](mailto:yrosenther@aol.com)

**Tel:**  
240.453.6247

**Website:**  
<http://www.plantvax.com>



## Company Profile

**Industry Sector:** Biotechnology specializing in protection against, detection of and decontamination of organophosphate neurotoxins

**Company Overview:** PlantVax was founded by Dr. Yvonne Rosenberg in 2007 and is the first company to pioneer an aerosolized form of a recombinant human butyrylcholinesterase (aer-rHuBChE) pretreatment against exposure to inhaled organophosphate (OP) neurotoxins, such as pesticides and nerve agents. PlantVax is distinguished as being granted the status of preferred vendor to the US Government's prime contractor for OP disclosure and decontaminant systems.

**Target Market(s):** Civilian and military personnel globally exposed to OP based neurotoxins.



## Key Value Drivers

**Technology\*:** Recombinant products produced in expensively in both mammalian and plant expression systems at high levels.

**Competitive Advantage:** PlantVax has approved IP on the aerosolized delivery of an antidotal bioscavenger against OPs. Several inhalation devices have been tested against different OPs in nonhuman primates. In addition, PlantVax has been selected as the preferred supplier to FLIR for related cholinesterase products in support of OP environmental detection programs.

**Plan & Strategy:** Complete preclinical testing, perform clinical trials and obtain FDA approval with corporate partners.



## Management

### Leadership:

Yvonne Rosenberg - Owner, Founder, CEO  
David Howgill - Director Commercialization  
Lori Urban - Senior scientist

### Scientific Advisory Board:

Dr. Arletty Pinel, Former Chief Reproductive Health, UNFPA  
Dr. Rainer Fischer, Director, Fraunhofer Institute, Aachen, Production SME  
James Fink, Clinical Director Aerogen  
Walter Raleigh, Business SME  
Dudley Quinlivan, Business SME



## Product Pipeline

**1. Pipeline One:** PlantVax's OP pretreatment has almost completed preclinical testing in macaques and will undergo Phase I clinical trials in Asia where high use of toxic pesticides exists. An early meeting has been held with the FDA.

**2. Pipeline Two:** PlantVax products in detection devices are currently in use and growing. Hazmat teams and other markets for a total commitment of over 1 billion units so far for product in disclosure sprays over 10 years.

**3. Pipeline Three:** A new biologically active bioscavenger molecule has been successfully produced in plants and is currently being tested for decontamination. Larger market potential than the existing disclosure market.